Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 3/20 | 0.32 |
| ▸ | CCND1 | P24385 | 3/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718221 | 0.73 | KDM4E (0.37) | CDK4CCND1ALDH1A1KDM4EATM | |
| SCHEMBL3849038 | 0.71 | CA12 (0.34) | CDK4CCND1CYP2A6ALOX12ALDH1A1 | |
| SCHEMBL127255 | 0.71 | DAO (0.35) | CDK4CCND1CYP2A6ALOX12ALDH1A1 | |
| SCHEMBL2073630 | 0.71 | CDK4 (0.32) | NOS2CDK4CCND1CYP2A6ALOX12 | |
| SCHEMBL570353 | 0.71 | CDK4 (0.32) | CDK4CCND1CYP2A6ALOX12ALDH1A1 | |
| SCHEMBL137023 | 0.71 | CA12 (0.39) | CDK4CCND1CYP2A6ALOX12ALDH1A1 | |
| SCHEMBL2073401 | 0.71 | CDK4 (0.32) | CDK4CCND1CYP2A6ALOX12BIRC5 | |
| SCHEMBL7781747 | 0.67 | HTR3A (0.43) | CYP2A6ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2071020 | 0.67 | SMN1; SMN2 (0.38) | CYP2A6ALDH1A1MAPTCYP1A2CA12 | |
| SCHEMBL15271285 | 0.67 | RECQL (0.35) | CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| EP-4392140-A1 | IN VITRO TRANSCRIPTION TECHNOLOGIES | BioNTech SE (DE) | 2024-07-03 | — | — | EP | disclosed |
| US-12018260-B2 | Tunable Reversir™ compounds | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-115038790-B | Synthesis of 3' -RNA oligonucleotides | 阿尔尼拉姆医药品有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240200061-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | ALNYLAM PHARMACEUTICALS, INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2024123993-A1 | SELECTIVE APOPTOSIS-INDUCING METHODS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4380576-A2 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | Verve Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-12005074-B2 | Extrahepatic delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240175020-A1 | COMPOSITIONS OF MODIFIED TREMS AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2024-05-30 | — | — | US | disclosed |
| US-20240175028-A1 | DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA | ALNYLAM PHARMACEUTICALS, INC (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2006037996-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | disclosed |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| EP-0483881-B1 | 3-Amidoindolyl derivatives | MERRELL PHARMA INC (US) | 1998-01-21 | — | — | EP | disclosed |
| US-5703107-A | CENTRAL NERVOUS SYSTEM DISORDERS; ANALGESICS; ANTIEPILEPTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-5675018-A | 3-amidoindolyl derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-10-07 | — | — | US | disclosed |
| US-5491153-A | 3-amidoindolyl derivative | MERRELL DOW PHARMACEUTICALS INC. (US) | 1996-02-13 | — | — | US | disclosed |
| US-5189054-A | 3-amidoindolyl derivatives and pharmaceutical compositions thereof | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0483881-A1 | 3-Amidoindolyl derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12005074-B2 | Extrahepatic delivery | RNASE1, SLC10A1, FABP1 | NOS2 3736/4885CDK4 4694/4885CCND1 4608/4885 |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | PMP22, ADCYAP1R1, CYP11B2 | NOS2 3530/4885CDK4 1953/4885CCND1 3590/4885 |
| US-12018260-B2 | Tunable Reversir™ compounds | SNRPE, PLK1, LDLR | NOS2 3590/4885CDK4 1576/4885CCND1 2788/4885 |
| US-20240175028-A1 | DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA | ELAVL1, HNRNPA1, ELAVL3 | NOS2 3088/4885CDK4 4695/4885CCND1 4258/4885 |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | NT5C3B, DERA, DUT | NOS2 2005/4885CDK4 2764/4885CCND1 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.